drugset
drugset / Trial / NCT02182102

Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer

NCT02182102 ↗

Phase 1 Completed 26 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

The primary objective was to determine the safety, tolerability and maximum tolerate dose (MTD) of BIBF 1120 in combination with pemetrexed. Secondary objectives were to characterize the pharmacokinetic profiles of BIBF 1120 and pemetrexed and to obtain preliminary anti-tumour efficacy information.

Timeline

Start
2005-09
Primary completion
2010-05
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Nintedanib Small molecule — Oral
Subject Pemetrexed Small molecule — —

Indications

non-small cell lung carcinoma